Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-24T07:38:24.520Z Has data issue: false hasContentIssue false
  • English
  • Français

Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease

Published online by Cambridge University Press:  23 September 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue 5 , September 2013 , pp. 623 - 624
Copyright
Copyright © The Canadian Journal of Neurological 2013

References

1.Massoud, F, Léger, G.Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–88.Google Scholar
2.Gauthier, S, Patterson, C, Chertkow, H, et al.4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can J Neurol Sci. 2012;39(6 Suppl 5):S1–8.Google ScholarPubMed
3.Birks, J, Harvey, RJ.Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006 (1):CD001190.Google Scholar
4.Birks, J, Grimley Evans, J, Iakovidou, V, Tsolaki, M.Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191.Google Scholar
5.Loy, C, Schneider, L.Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747.Google Scholar
6.Saleh, S, Kirk, A, Morgan, DG, Karunanayake, C.Less education predicts anticholinesterase discontinuation in dementia patients. Can J Neurol Sci. 2013;40(5):684–90.Google Scholar
7.Amuah, JE, Hogan, DB, Eliasziw, M, et al.Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19(7):670–9.Google Scholar
8.Herrmann, N, Binder, C, Dalziel, W, Smyth, S, Camacho, F.Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009;26(5)403–7.Google Scholar
9.Massoud, F, Dorais, M, Charbonneau, C, Lescrauwaet, B, Boucher, JM, LeLorier, J.Drug utilization review of cholinesterase inhibitors in Quebec. Can J Neurol Sci. 2008;35(4):508–9.Google Scholar
10.Gardette, V, Andrieu, S, Lapeyre-Mestre, M, et al.Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs. 2010;24(5):431–42.Google ScholarPubMed
11.Massoud, F, Desmarais, JE, Gauthier, S.Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011;23(3):372–8.Google Scholar
12.Lopez, OL, Becker, JT, Wahed, AS, et al.Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–7.Google Scholar